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Summary Seventeen patients with terminal malignancy have been entered into a sequential investigation of
two doses of continuous infusion recombinant interleukin-2 (bioleukin) given in the setting of a general ward.
After an initial experience of a dose of 300 ug m-2 in eight patients the remainder received 400 gg m-2.
Temporary interruption of treatment at the first sign of any serious toxicity led to rapid resolution of side-
effects. No patient needed intensive care support, although nine of 17 required temporary interruption of
infusion, lasting on average 4 h. Median lymphocyte rebound on day 14 was 3.6 times the pre-treatment level.
It remained above pre-treatment levels in four of five patients who had not shown disease progression at day
56 after more than 28 days off treatment. Minor responses occurred in five patients, lasting on average 4
months.
Over the past 3 years it has become increasingly evident that
interleukin-2 (rIL-2) when given in combination with lym-
phokine activated killer (LAK) cells can produce complete
remission in approximately 10% of patients with metastatic
renal cell carcinoma or malignant melanoma (Rosenberg et
al., 1985, 1987). This was at the price of considerable tox-
icity, often needing intensive care unit support, although
West et al. (1987) suggested that if rIL-2 was given by
continuous infusion. ICU support was required less fre-
quently.
Recently, review of the cumulative data from unran-
domised trails suggests that there is little evidence to establish
the superiority of the combination of rIL-2 and LAK over
rIL-2 alone in terms of overall response (Louie et al., 1989),
despite initial analysis of the only randomised trial suggesting
that the incidence of durable complete remission in patients
receiving combined treatment may be significantly higher
(Rosenberg, 1989). Recent reports have suggested that if the
total number of days of rIL-2 treatment is increased from 10
to 20 and the rIL-2 given by continuous infusion in 5-day
pulses, the initial response rate may be as good as that
reported for combined IL-2/LAK (Paciucci et al., 1988).
However, as yet the incidence of long-term durable CRs has
not yet been reported.
Although preclinical and preliminary clinical testing have
been reported on at least four different recombinant IL-2
preparations (Thurman et al., 1986), the majority of
literature reports refer to clinical data using the Cetus prod-
uct. The amino acid sequence of this material differs from
natural IL-2 by a single amino acid substitution (cysteine at
position 125 has been replaced by serine), and there is an
additional mathionine residue at the N-terminal end.
Recently early clinical results have been reported using
short-term infusions of bioleukin (Marolda et al., 1987;
Gambacorti-Passerini, 1988; Kern et al., 1985). This prepara-
tion of rIL-2 preserves the native amino acid sequence, but
does have the additional methionine at the N-terminal end.
In the previously mentioned blinded preclinical screen (Thur-
man et al., 1986), this material compared very favourably to
the others tested. This paper reports the results of
preliminary testing of two relatively low doses of bioleukin in
a group of patients with terminal cancer receiving bioleukin
by a 5-day continuous infusion schedule. Because of previous
reports correlating response with levels of rebound lym-
phocytosis (West et al., 1987) this parameter has been used to
monitor the biological effect of treatment.
Patients and methods
Patients with terminal testicular, renal and prostate cancer
and malignant melanoma who had failed prior conventional
treatment were treated with IL-2 after giving written in-
formed consent. All had symptoms from tumour metastases
and most had WHO performance status 2 or 3. All had at
least 3 weeks from completion of previous thereapy and most
of the patients with testicular tumour had a life expectancy of
less than 3 months.
Dosage
The starting dose was 300ygm-2 (1.7-3.2 x 106mCi mg'
specific activity). The first two patients received 3-day
infusions and all subsequent patients received 5-day
infusions. The dosage was escalated to 400 Lg m-2 after the
first eight patients. This latter group of nine patients, after
two 5-day periods of continuous infusion treatment in 14
days, went on to receive 2 weeks of outpatient treatment at a
dose of 300 igm-2 given over 2 h, three times per week.
Patient monitoring
All patients had hourly temperature, pulse and blood pres-
sure measurements and were weighed and had routine
haematology, renal and liver function performed daily. No
pressor drugs or volume expanding treatments were given,
and it was planned that hypotension (BP < 80/60), severe
(WHO grades 3 and 4) toxicity for any organ system or
patient distress would be considered as justification for tem-
porary suspension of infusion.
Results
Preliminary dosing experience
Table I summarises the tumour type, previous history, age
and treatment details of the individual patients. The initial
patients received shorter duration treatment and lower
dosage as part of familiarisation with the effect of treatment.
Apart from the first two patients who electively received
3-day cycles, there were three other patients who did not
receive two 5-day cycles of treatment because of the rapidity
of tumour progression. The remaining 12 patients received
two 5-day cycles in 14 days, and seven went on to receive the
final 2 weeks of outpatient treatment.
Correspondence: R.T.D. Oliver.
Received 27 April 1989; and in revised form 23 August 1989.
Br. J. Cancer (1989), 60, 934-937 '." The Macmillan Press Ltd., 1989BIOLEIKIN AND PERIPHERAL BLOOD LEUCOCYTES 935
Table I General description of patients
Previous Weeks No. ofdays
Tumour type treatment Age treatment IL-2
1. Seminoma R & C 41 2 7.5
2. Teratoma C 19 1 5
3. Teratoma C 21 2 9.5
4. Teratoma C &S 51 2 10
5. Teratoma C 25 1 5
6. Prostate R & H 56 4 16
7. Renal APD 59 2 7
8. Renal S 70 1 5
9. Melanoma S 63 2 10
10. Renal S & R 24 4 15
11. Melanoma S 43 4 15
12. Melanoma S 58 3 10
13. Melanoma S 52 4 11
14. Melanoma S 21 4 15
15. Squamous ca skin S 25 4 15
16. Melanoma S 56 2 5
17. Melanoma S & R 53 4 16
R, radiotherapy; H, hormone therapy; C, chemotherapy; S, surgery; APD, diphosphonate.
Biological effects of treatment
Table II summarises the effects of rIl-2 treatment on lym-
phocyte and eosinophil counts which were the haemopoetic
elements most effected by treatment. Table III summarises
the toxicity experienced by individual patients. Nine of 17
patients had temporary interruptions of treatment lasting for
1-14 h (median 4) because of toxicity. Three of 17 showed
almost doubling of pretreatment creatinine during the first
5-day cycle and five of 12 during the second 5-day cycle.
Hepatic transaminase levels (ALT) doubled in four of 17
during the first 5-day course, eight of 12 during the second
cycle. Nine of 17 showed weight gain on treatment, although
in all instances it was less than 10% of the initial body
weight. Each of these toxicities resolved rapidly on interrup-
tion of the infusion, and no patient was left with lasting
sequelae. All patients showed a degree of lymphocytosis 48 h
after discontinuing treatment.
Table IV demonstrates the correlation between initial lym-
phocyte count and nadir lymphocyte count and degree of
rebound lymphocytosis. Those with a low lymphocyte count
pretreatment generally had a lower rebound on stopping
rIL-2. These were predominantly those who had been heavily
pretreated with radiation or chemotherapy, although in the
intermediate group there were patients with a low count
possibly related to the extent of their disease.
Table V demonstrates that although there is a higher
rebound lymphocytosis and level of serum creatinine in the
patients, tolerating the higher doses of IL-2, paradoxically,
this group had less deranged liver function.
Response to treatment
Table VI summarises the responses seen. There were no
complete or partial responses according to WHO criteria.
One of three renal cell patients had a >50% reduction of
<2 cm cutaneous deposits for 3 months, but no change in a
10 cm local recurrence in the renal bed (case no. 10). One of
the seven melanomas showed less than 50% regression of
liver metastases on CT scan but with normalisation of meta-
stasis induced liver function abnormality (case no. 11). The
patient with prostate cancer (case no. 6) had complete nor-
malisation of acid phosphatase levels, associated with resolu-
tion of bone pain and minor shrinkage of pelvic nodes. He
remained progression-free for 5 months, and when re-treated
12 months after his first treatment responded with a further
normalisation of acid phosphatase and resolution of bone
pain.
Discussion
This study has established that 400 fgm2 bioleukin daily
for 5 days a week for 2 weeks, the upper of the two doses
studied (300-400ytg m-2) can be safely given in the setting of
a general medical ward, and that when given to patients who
do not have lymphopoenia as a consequence of previous
radiotherapy, chemotherapy or extent of disease, there is
major rebound lymphocytosis with counts rising to 4-5 times
pretreatment levels.
Preliminary results from T cell phenotyping studies show
Table II Effect of rlL-2 on leucocyte counts
Day 0 Day I Day 7 Day 14 Day 56
lyleos (total IL-2 lyleos (total IL-2 ly/eos (total IL-2
lyleosa ly/eos dose in tsg) dose in fg) dose in jug)
1. 0.5/0.9 0.3/- 0.8 /0.15 (1.8)
2. 0.7/0 0.3/0.3 1.0 /0.04 (2.4)
3. 1.0/0.3 0.3/- 2.3 /5. 6 (1.4) 6.6/3. 6 (4.8)
4. 2.4/0.1 n.d. ND 10.0/3.1 (4.9)
5. n.d. 0.1/- 4.4 /0. 1 (2.7)
6. 2.4/0.72 0.3/0.41 3.6 /2. 7 (1.2) 7.1/9.9 (2.0) 3.7/0.13 (4.2)
7. 1.8/0.0 0.5/- 1.8 /0.23 (0.9)
8. n.d./- 0.13/0.7 1.5 /0.21 (1.7)
9. 3.0/0.28 0.8/0.42 13.8 /0.93 (3.1) 14.1 /5.8 (5.7)
10. 0.6/0.52 0.1/0.51 1.88/1.42 (1.5) 1.9 /3.3 (2.8) 1.2/0.6 (4.6)
11. 2.4/0/07 0.6/0.09 10.9 /0.77 (4.0) 11.8 /6.67 (6.5) 3.2/0.08 (8.3)
12. 2.0/0 1.3/0.07 1.98/0.06 (2.1) 3.39/0.24 (2.7)
13. n.d. 0.4/0.15 0.51/0 (2.4) 7.34/3.95 (4.5) 3.0/0.29 (5.7)
14. 2.1/0.3 0.4/2.0 9.9 /6. 1 (1.3) 4.1 /0.08 (3.2) 2.5/0.17 (6.0)
15. 2.0/0.42 0.2/1.2 6.36/4.06 (2.5) 8.48/7.39 (6.7) 2.0/0.43 (8.70
16. 1.6/0.09 0.3/0.06 0.3 /0.24 (2.5) 2.6 /1. 7 (4.2) -
17. 1.3/0 0.1/0 4.8 /0.04 (4.0) 5.2 /9.6 (7.3)
aly, lymphocytes x 1091-'; eos, eosinophyls x 1091-'.936 R.T.D. OLIVER et al.
Table III Toxicity summary chart
Dominant
Day 0 Day 4/5 Day 11/12 Day 56 physical toxicity
creat/alr3 creat/alt creat/alt creat/alt Weight gainb (WHO grade)
1. 70/40 60/31 3/72 Fever (2)
2. 77/14 120/ 25 3/50 Vomiting (2), hypotension
3. 71/23 120/ 39 137/91 - 3/66 Vomiting (2)
4. 212/16 369/25 425/58 2/70 Skin erythema (2)
5. 74/ND 87/55 0/59 Fever (2)
6. 121/10 145/105 235/48 3/81 Renal (2), staph skin infection (1)
7. 105/12 142/4 - 3/60 Hypotension
8. 157/32 342/26 0/67 Hypotension
9. 111/40 220/237 206/77 0/65 Vomiting (2), somnolence (3)
10. 143/32 130/87 120/199 109/12 1/70 Respiratory distress (3)
11. 84/159 109/137 245/46 85/32 5/70 Perianal abscess (2)
12. 64/10 70/11 82/160 1/54 Vomiting (2), rigor (3)
13. 147/10 172/10 186/52 n.d./9 6/71 Skin erythema (2)
14. 94/37 85/69 102/15 1/54 Vomiting (2), hypotension
15. 104/27 110/35 114/29 Nausea (1)
16. 90/11 77/10 132/15 3.6/51.7 Nausea, diarrhoea (1)
17. 90/4 262/121 300/50 n.d. 4/80 Vomiting (2), hypotension,
ulcer at drop site (HCO3) (2)
acreat, creatinine (normal level 25-120 mmol I'); alt, alanine-aminotransferase (normal level 7-45
i.u. 1'). Toxicity in bold indicates severeenough to suspend infusion temporarily. bWeightgain in kg/initial
starting weight in kg.
Table IV Influence of pre-treatment lymphocyte count on rebound
Pre Rx lymphocyte No. of Nadir Rebound Rebound
count ( x I0 1') cases day 1/2 day 7 day 14
< 1.0 3 0.2 1.2 1.9
1 -1.9 4 0.3 2.3 4.8
>2.0 6 0.6 7.7 8.2
that this increase is proportionately more in the T8 subset in,
as others have reported, association with augmentation of
both spontaneous and in vitro rIL-2 primed cytotoxicity
against lymphoblastoid cell lines (A. Nouri & M. Lacey,
unpublished).
These results are similar to those reported by Lotze et al..
(1985) using the Cetus modified rIL-2 in their preclinical
testing, where they document a 5-fold increase in lym-
phocytes at 48 h after discontinuation of treament.. Similar
data have been noted by West et al. (1987) and Thompson et
al. (1988), although their report showed levels slightly higher
than those reported in this paper. Although precise
equivalence of unitage is difficult to establish, on the basis of
specific acitivity determined in our laboratory the upper dose
in this study (400 jtg m-2 ) does approximate to that of
5 x 106 Cetus units m-2 which was the upper limit of West et
al. (1987). The equivalence of lymphocyte rebound would
support this contention.
As yet there is no uniform agreement about which
parameter of immune response gives the best correlation with
chance of response to treatment. Some authors have noted a
correlation with level of in vivo LAK activation (Paciucci et
al., 1988) while others have shown a correlation with lym-
phocytosis (West et al., 1987). The relative ease of documen-
ting lymphocyte response has obvious advantages and more
information is required comparing its discriminatory power
with in vivo LAK activation.
Currently, controversy exists as to whether bolus or con-
tinuous infusion provides the best method of delivery of
rIL-2. The acute toxic effects of a high dose bolus every 8 h
are more pronounced, although higher daily doses can be
TableVI Response to bioleukin treatment
Duration
n MR (months)
Renal cell ca. 3 1 3
Melanoma 7 2 3,5
Germ cell tumour 5 - -
Prostateca. I 1 5
Squamousca. skin I 1 4
n, no. ofcases treated; MR, minor response.
given by bolus injections. At the end of 5 days it is unlikely
that there is much difference in the cumulative toxicity
although there is some evidence from one author (Kohler et
al., 1987) that the level of rebound is higher in patients
receiving continuous i.v. infusion compared to i.v. bolus. In
addition, at least one study in experimental animals has
suggested that the therapeutic effect of interleukin-2 is more
closely correlated with the area under the curve than the
actual peak level obtained (Cheever et al., 1985). However,
more substantial clinical data are required, as currently only
for the intermittent bolus regimen is there evidence that
patients have sustained durable complete remissions beyond
2 years (Rosenberg et al., 1987, 1989).
Most patients in this study showed some toxicity and in
nine of 17 this led to temporary interruption of treatment.
None had irreversible toxicity and all showed improvement
within 30-45 min of stopping treatment. The paradox
reported in Table V, although possibly only a reflection of
the small number of patients studied to date, is a factor
noted from other studies, i.e. that different patients get a
different predominant side-effect and that there is not neces-
sarily a correlation between intensity of one side-effect and
another. In this study intensity of nausea and liver enyzme
changes seemed to be correlated. This may have led to earlier
treatment interruption than rising urea becuase it caused
greater physical distress to the patients.
A further issue is how far toxicity should temper dosage
modification. In the bolus studies the aim has been to sustain
Table V Correlation between ril-2 dose tolerated and haematological and biochemical
effects
Total
bioleukin No. of
dose (days 1-14) cases Lymphocytes Eosinophils Creatinine Alt'
<4.5gg 5 4.4 3.2 140 91
>4.5gLg 7 9.4 5.0 238 59
aAlanine-aminotransferase (normal level 7-45 i.u.l-').BIOLEIKIN AND PERIPHERAL BLOOD LEUCOCYTES 937
the dosage as long as toxicity was not life-threatening
(Rosenberg et al., 1985, 1987), while in the patients reported
in this paper dosage has been temporarily interrupted at the
earliest sign of patient intolerance. As the authors of the
bolus regimen have published data showing that steroids may
abrogate the beneficial effects of IL-2 (Vetto et al., 1987) it is
possible that there could be advantages in not stressing
patients to the limits of tolerance, particularly in view of
reports from animal studies (Talmadge et al., 1987) and the
cumulative data from use of interferon in patients with renal
cell carcinoma (Kirkwood et al., 1984) suggesting that there
may be a bell shaped dose-response curve for some
immunologically based treatments. The early indications of
response in the series of patients reported in this paper, and
the observation of one partial and one mixed response in the
first four patients in our subsequent ongoing phase 2 study,
suggest that further investigations of this less aggressive app-
roach is justified.
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